Low potency topical steroids

Recently a new disease has been described called the “Localized Eye Area Sensitivity Syndrome”. This disease was reported by Stephens T J et al in 1990 (see attached paper describing condition with all appropriate references). This disease demonstrates the irritancy potential of topical preparations around the eyes and clearly indicates the need for the invention described herein. There is a definite urgency for the development of the invention, since it is needed for patients with ophthalmologic and dermatologic dermatosis in the region of the eye and within the eye. Localized Eye Area Sensitivity Syndrome (LEASS) has been described as a collection of both subjective and objective symptoms which occur when susceptible individuals apply topical products containing certain chemicals to the periorbital area.

The obvious priority is immediate discontinuation of any further topical corticosteroid use. Protection and support of the impaired skin barrier is another priority. Eliminating harsh skin regimens or products will be necessary to minimize potential for further purpura or trauma, skin sensitivity, and potential infection. Steroid Atrophy [10] [11] is often permanent, though if caught soon enough and the topical corticosteroid discontinued in time, the degree of damage may be arrested or slightly improve. However, while the accompanying Telangectasias may improve marginally, the Striae is permanent and irreversible. [1]

Low potency topical steroids

low potency topical steroids


low potency topical steroidslow potency topical steroidslow potency topical steroidslow potency topical steroidslow potency topical steroids